PMID- 21668683
OWN - NLM
STAT- MEDLINE
DCOM- 20120207
LR  - 20220309
IS  - 1750-2659 (Electronic)
IS  - 1750-2640 (Print)
IS  - 1750-2640 (Linking)
VI  - 5
IP  - 6
DP  - 2011 Nov
TI  - An integrated, multistudy analysis of the safety of Ann Arbor strain live 
      attenuated influenza vaccine in children aged 2-17 years.
PG  - 389-97
LID - 10.1111/j.1750-2659.2011.00243.x [doi]
AB  - BACKGROUND: Trivalent, Ann Arbor strain, live attenuated influenza vaccine (LAIV) 
      is approved in several countries for use in eligible children aged >/=2 years. 
      OBJECTIVE: To describe the safety of Ann Arbor strain LAIV in children aged 2-17 
      years. METHODS: An integrated analysis of randomized, controlled trials of LAIV. 
      RESULTS: A total of 4245 and 10,693 children received >/=1 dose of LAIV in year 1 
      of 6 trivalent inactivated influenza vaccine (TIV)-controlled and 14 
      placebo-controlled studies, respectively; 3212 children were revaccinated in year 
      2 of 4 placebo-controlled studies. Compared with placebo for days 0-10 
      post-vaccination, LAIV recipients exhibited increased runny/stuffy nose (+7%), 
      headache (+7%), and tiredness/decreased activity (+2%) after dose 1; and a higher 
      rate of decreased appetite (+4%) after year 2 revaccination. Compared with TIV, 
      only runny/stuffy nose was increased (dose 1, +12%; dose 2, +4%). Compared with 
      initial vaccination, LAIV reactogenicity was lower after dose 2 in year 1 and 
      revaccination in year 2. Unsolicited adverse events (AEs) increased with LAIV in 
      some comparisons were headache, nasal congestion/rhinorrhea, rhinitis, and 
      pyrexia; ear pain and lower respiratory illness were decreased. There was no 
      evidence of an increase in any potential vaccine-related serious AE in LAIV 
      recipients. Among children aged 2-17 years and specifically aged 24-35 months, 
      there was no evidence that lower respiratory illness or wheezing illness occurred 
      at a higher rate in LAIV recipients. CONCLUSION: This analysis supports the 
      safety of Ann Arbor strain LAIV in children aged 2-17 years and provides a 
      consensus assessment of events expected after vaccination.
CI  - (c) 2011 Blackwell Publishing Ltd.
FAU - Ambrose, Christopher S
AU  - Ambrose CS
AD  - MedImmune LLC, Gaithersburg, MD, USA. ambrosec@medimmune.com
FAU - Yi, Tingting
AU  - Yi T
FAU - Falloon, Judith
AU  - Falloon J
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20110404
PL  - England
TA  - Influenza Other Respir Viruses
JT  - Influenza and other respiratory viruses
JID - 101304007
RN  - 0 (Influenza Vaccines)
RN  - 0 (Vaccines, Attenuated)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Influenza Vaccines/*administration & dosage/adverse effects
MH  - Influenza, Human/*prevention & control/virology
MH  - Male
MH  - Vaccination
MH  - Vaccines, Attenuated/administration & dosage/adverse effects
PMC - PMC3256242
EDAT- 2011/06/15 06:00
MHDA- 2012/02/09 06:00
PMCR- 2011/11/01
CRDT- 2011/06/15 06:00
PHST- 2011/06/15 06:00 [entrez]
PHST- 2011/06/15 06:00 [pubmed]
PHST- 2012/02/09 06:00 [medline]
PHST- 2011/11/01 00:00 [pmc-release]
AID - IRV243 [pii]
AID - 10.1111/j.1750-2659.2011.00243.x [doi]
PST - ppublish
SO  - Influenza Other Respir Viruses. 2011 Nov;5(6):389-97. doi: 
      10.1111/j.1750-2659.2011.00243.x. Epub 2011 Apr 4.